Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Post by dollarhunteron Oct 11, 2004 3:28pm
91 Views
Post# 8035224

Annual Shareholders Meeting

Annual Shareholders MeetingDid everybody get their package in the mail last week? Regards, DH Media Advisory: Adherex Technologies Establishes Satellite Location in Ottawa for its Annual Shareholders Meeting 10/11/04 OTTAWA, ONTARIO, Oct 11, 2004 (CCNMatthews via COMTEX) -- Adherex Technologies Inc. (TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, will hold its Annual and Special Meeting of Shareholders on Friday, October 22, at the Sofitel Montreal, 1155 rue Sherbrooke, M ontreal, Quebec at 4 p.m. EDT. The Company announced today that it has also established a satellite location in Ottawa where shareholders may participate in the meeting by interactive videoconference. Ottawa Satellite Location: University of Ottawa 129 Louis Pasteur Room LPR285 Ottawa, Ontario K1N 6N5 Directions: From downtown, take Laurier Ave. east to King Edward Ave. heading south. Turn right on Marie Curie to Louis Pasteur. For further help with directions, call Marc Villeneuve, 613-562-5800 x6307.
Bullboard Posts